Septerna, Inc.
Septerna, Inc. (Nasdaq: SEPN) is a clinical-stage biotechnology company developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). Its proprietary Native Complex Platform reconstitutes functional GPCRs outside cells to support structural analysis, screening and optimization of drug… From the company’s description.
In fiscal 2025, Septerna, Inc. reported revenue of $45.95M, up 4174.5% from fiscal 2024, and a net loss of $48.88M. Its operating margin was −148.6%, and operations generated $110.19M in cash. Over the twelve months to Jun 30, 2026, revenue was $98.88M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Septerna, Inc. does
In the company’s own words
Septerna, Inc. (Nasdaq: SEPN) is a clinical-stage biotechnology company developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). Its proprietary Native Complex Platform reconstitutes functional GPCRs outside cells to support structural analysis, screening and optimization of drug candidates. The company’s wholly owned pipeline focuses on endocrinology, immunology and inflammation, and metabolic diseases. Its programs include SEP-479, a PTH1R agonist in development for hypoparathyroidism, and SEP-631, an MRGPRX2 negative allosteric modulator initially developed for chronic spontaneous urticaria; the latter completed a Phase 1 trial in 2026. Septerna also has a collaboration with Novo Nordisk to discover and develop oral small-molecule therapies for metabolic diseases involving the GLP-1, GIP and glucagon receptors. The company’s potential medicines are intended for patients with endocrine, inflammatory, immune and metabolic disorders. Its website is https://www.Septerna.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1984086
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Septerna, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Septerna, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Septerna, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Septerna, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Septerna, Inc.'s last four quarterly filings that the numbers alone won't show?”